Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Advertising

Press Release

NeoRecormon (epoetin beta; Roche/Chugai) Drug Analysis Report 2018 - ResearchAndMarkets.com

Research and Markets
Posted on: 21 Feb 18

The "Drug Analysis: NeoRecormon" drug pipelines has been added to ResearchAndMarkets.com's offering.

NeoRecormon (epoetin beta; Roche/Chugai) is an erythropoiesis-stimulating agent (ESA) administered by intravenous (IV) or subcutaneous (SC) injection, and is indicated for the treatment of anemia in chronic kidney disease (CKD). The drug consists of recombinant human erythropoietin and targets the erythropoietin receptor, initiating the same pathway as native erythropoietin and triggering increased blood production in bone marrow (EMC, 2017). NeoRecormon is comparable to Epogen (epoetin alfa; Amgen/Kyowa Hakko Kirin/Johnson & Johnson) in terms of its clinical profile, with similar safety, efficacy, and dosing.

Key Topics Covered:

Product Profiles

NeoRecormon: Anemia in chronic kidney disease

List of Figures

Figure 1: NeoRecormon sales for anemia in chronic kidney disease across Japan and the five major EU markets, by country, 2015-24

List of Tables

Table 1: NeoRecormon sales for anemia in chronic kidney disease across Japan and the five major EU markets, by country ($m), 2015-24

For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/vdgpqh/neorecormon?w=4

View source version on businesswire.com: http://www.businesswire.com/news/home/20180221006127/en/

Business Wire
www.businesswire.com

Last updated on: 21/02/2018

Advertising
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.